Role of MYC in medulloblastoma

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 11, 2013, Pages

  Roussel, Martine F ^a   Robinson, Giles W ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EZH2 INHIBITOR; MEVINOLIN; MICRORNA; MYC PROTEIN; PROTEIN INHIBITOR; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; COPY NUMBER VARIATION; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMAN; LYMPHOMA; MEDULLOBLASTOMA; METASTASIS; NONHUMAN; POSTERIOR FOSSA; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; WNT SIGNALING PATHWAY;

CEREBELLAR NEOPLASMS; CRANIAL FOSSA, POSTERIOR; EPIGENESIS, GENETIC; GENE AMPLIFICATION; GENES, MYC; HUMANS; MEDULLOBLASTOMA; MICRORNAS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84887136898     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a014308     Document Type: Article

References (94)

1. Ayrault O., Zindy F, Rehg J, Sherr CJ, Roussel MF. 2009. Two tumor suppressors, pp27Kip1 and patched-1, collaborate to prevent medulloblastoma. Mol Cancer Res 7: 33-40.
2. Ayrault O., Zhao H, Zindy F, Qu C, Sherr CJ, Roussel MF. 2010. Atoh1 inhibits neuronal differentiation and collaborates with Gli1 to generate medulloblastoma-initiating cells. Cancer Res 70: 5618-5627.
3. Bai A. H, Milde T, Remke M, Rolli CG, Hielscher T, Cho YJ, Kool M., Northcott PA, Jugold M, Bazhin AV, et al. 2012. MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. ActaNeuropathol 123: 529-538.
4. Berg T., Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J., Boger DL, Vogt PK. 2002. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci 99: 3830-3835.
5. Blackwood E. M, Eisenman RN. 1991. Max: A helix-loophelix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251: 1211-1217.
6. Blobel G. A, Kalota A, Sanchez PV, Carroll M. 2011. Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemia. Cancer Cell 20: 287-288.
7. Bradner J. 2013. Inhibiting Myc. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014266.
8. Campbell KJ, White RJ. 2013. MYC regulation of cell growth through control of RNA polymerae I and III activities. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect. a018408.
9. Carramusa L., Contino F, Ferro A, Minafra L, Perconti G, Giallongo A., Feo S. 2007. The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells. J Cell Physiol 213: 511-518.
10. Chang C. J, Hung MC. 2012. The role of EZH2 in tumour progression. Br J Cancer 106: 243-247.
11. Chappell J, Dalton S. 2013. Roles for MYC in the establishment and maintenance of pluripotency. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014381.
12. Cho Y. J, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, et al. 2011. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29: 1424-1430.
13. Clifford S. C, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, StraughtonD, EllisonDW. 2006. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 5: 2666-2670.
14. Dang CV. 2013. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 3: a014217.
15. de Haas T, Hasselt N, Troost D, Caron H, Popovic M, Zadravec-Zaletel L., GrajkowskaW, PerekM, Osterheld MC, Ellison D., et al. 2008. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. Clin Cancer Res 14: 4154-4160.
16. Delmore J. E, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
17. Dubuc A. M, Remke M, Korshunov A, Northcott PA, Zhan SH, Mendez-Lago M, Kool M, Jones DT, Unterberger A, Morrissy A. S, et al. 2013. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol 125: 373-384.
18. Eilers M., Eisenman RN. 2008. Myc's broad reach. Genes Dev 22: 2755-2766.
19. Ellison D. W, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC. 2005. β-Catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23: 7951-7957.
20. Ellison D. W, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G., Kenney AM, Brat DJ, Perry A, Yong WH, et al. 2011a. Medulloblastoma: Clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121: 381-396.
21. Ellison D. W, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan S. L, ZhaoW, Nicholson SL, Taylor RE, Bailey S, et al. 2011b. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29: 1400-1407.
22. Ferretti E., De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola M. S, Di Rocco C, Riccardi R, Giangaspero F, Farcomeni A., et al. 2009. MicroRNA profiling in human medulloblastoma. Int J Cancer 124: 568-577.
23. Filippakopoulos P., Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. 2010. Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
24. Gabay M, Li Y, Felsher DW. 2013. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014241.
25. Gajjar A., Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant T. E, Woo S, Wheeler G, Ahern V, Krasin MJ, et al. 2006. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 7: 813-820.
26. Gibson P., Tong Y, Robinson G, Thompson MC, Currle DS, Eden C., Kranenburg TA, Hogg T, Poppleton H, Martin J, et al. 2010. Subtypes of medulloblastoma have distinct developmental origins. Nature 468: 1095-1099.
27. Goodrich L. V, Milenkovic L, Higgins KM, Scott MP. 1997. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 277: 1109-1113.
28. Hallahan A. R, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton B. A, Russell TL, Ellenbogen RG, Bernstein ID, Beachy P. A, et al. 2004. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 64: 7794-7800.
29. Hatton B. A, Villavicencio EH, Tsuchiya KD, Pritchard JI, Ditzler S., Pullar B, Hansen S, Knoblaugh SE, Lee D, Eberhart C. G, et al. 2008. The Smo/Smo model: Hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res 68: 1768-1776.
30. He L., Hannon GJ. 2004. MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531.
31. He T. C, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. 1998. Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
32. Hurlin P.J. 2013. Control of vertebrate development by MYC. Cold Spring Harb Perspect Med doi: 10.1101/ cshperspect.a014332.
33. Jones D. T, Jager N, Kool M, Zichner T, Hutter B, Sultan M, Cho Y. J, Pugh TJ, Hovestadt V, Stutz AM, et al. 2012. Dissecting the genomic complexity underlying medulloblastoma. Nature 488: 100-105.
34. Kawauchi D., Robinson G, Uziel T, Gibson P, Rehg J, Gao C, Finkelstein D., Qu C, Pounds S, Ellison DW, et al. 2012. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 21: 168-180.
35. Kenney A. M, Cole MD, Rowitch DH. 2003. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 130: 15-28.
36. Kessler J. D, Hasegawa H, Brun SN, Emmenegger BA, Yang ZJ, Dutton JW, Wang F, Wechsler-Reya RJ. 2009. N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes Dev 23: 157-170.
37. Knoepfler P. S, Cheng PF, Eisenman RN. 2002. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 16: 2699-2712.
38. Knoepfler P. S, Zhang XY, Cheng PF, Gafken PR, McMahon SB, Eisenman RN. 2006. Myc influences global chromatin structure. EMBO J 25: 2723-2734.
39. Koh C. M, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. 2011. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptionalmechanisms. Oncotarget 2: 669-683.
40. Kool M., Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D., Meeteren NS, Caron HN, Cloos J, et al. 2008. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PloS ONE 3: e3088.
41. Kool M., Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott P. A, Cho YJ, Koster J, Schouten-van Meeteren A, van Vuurden D, et al. 2012. Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data ofWNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123: 473-484.
42. Lin C. H, Lin C, Tanaka H, Fero ML, Eisenman RN. 2009. Gene regulation and epigenetic remodeling in murine embryonic stem cells by c-Myc. PLoS ONE 4: e7839.
43. Louis D. N, Ohgaki H, WiestlerOD, Cavenee WK, Burger PC, Jouvet A., Scheithauer BW, Kleihues P. 2007. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
44. Lv S. Q, Kim YH, Giulio F, Shalaby T, Nobusawa S, Yang H, Zhou Z., Grotzer M, Ohgaki H. 2012. Genetic alterations in microRNAs in medulloblastomas. Brain Pathol 22: 230-239.
45. Malynn B. A, de Alboran IM, O'Hagan RC, Bronson R, Davidson L, DePinho RA, Alt FW. 2000. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev 14: 1390-1399.
46. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, et al. 2012. EZH2 inhibition as a therapeutic strategy for lymphomawith EZH2-activating mutations. Nature 492: 108-112.
47. McMahon SB, Wood MA, Cole MD. 2000. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 20: 556-562.
48. McManamy CS, Pears J, Weston CL, Hanzely Z, Ironside JW, Taylor R. E, Grundy RG, Clifford SC, Ellison DW. 2007. Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior. Brain Pathol 17: 151-164.
49. Mendell J.T. 2008. miRiad roles for the miR-17-92 cluster in development and disease. Cell 133: 217-222.
50. Milde T., Lodrini M, Savelyeva L, Korshunov A, Kool M, Brueckner L. M, Antunes AS, Oehme I, Pekrun A, Pfister SM, et al. 2012. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. JNeurooncol 110: 335-348.
51. Mulhern R. K, Palmer SL, Merchant TE, WallaceD, Kocak M, Brouwers P., Krull K, Chintagumpala M, Stargatt R, Ashley DM, et al. 2005. Neurocognitive consequences of riskadapted therapy for childhood medulloblastoma. J Clin Oncol 23: 5511-5519.
52. Murphy B. L, Obad S, Bihannic L, Ayrault O, Zindy F, Kaupinnen S, Roussel MF. 2013. Silencing of the miR-17_92 cluster family inhibits medulloblastoma progression. Cancer Res (to be published).
53. Nicodeme E., Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung C. W, Chandwani R, Marazzi I, Wilson P, Coste H, et al. 2010. Suppression of inflammation by a synthetic histone mimic. Nature 468: 1119-1123.
54. Northcott P. A, Fernandez LA, Hagan JP, Ellison DW, GrajkowskaW, Gillespie Y., Grundy R, Van Meter T, Rutka JT, Croce C. M, et al. 2009a. The miR-17/92 polycistron is upregulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69: 3249-3255.
55. Northcott P. A, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, Mack S, Kongkham PN, Peacock J, Dubuc A, et al. 2009b. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41: 465-472.
56. Northcott P. A, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, et al. 2011. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29: 1408-1414.
57. Northcott P. A, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P, Taylor MD, et al. 2012a. Medulloblastomics: The end of the beginning. Nat Rev Cancer 12: 818-834.
58. Northcott P. A, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T., Stutz AM, Korshunov A, Reimand J, Schumacher SE, et al. 2012b. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488: 49-56.
59. Oliver T. G, Grasfeder LL, Carroll AL, Kaiser C, Gillingham CL, Lin SM, Wickramasinghe R, ScottMP, Wechsler-Reya RJ. 2003. Transcriptional profiling of the Sonic hedgehog response: A critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci 100: 7331-7336.
60. Packer R. J, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson P. L, Bayer L, LaFond D, Donahue BR, Marymont MH, et al. 2006. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24: 4202-4208.
61. Park A. K, Lee SJ, Phi JH, Wang KC, Kim DG, Cho BK, Haberler C, Fattet S, Dufour C, Puget S, et al. 2012. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation. Neurooncol 14: 203-214.
62. Parsons D. W, LiM, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, et al. 2011. The genetic landscape of the childhood cancer medulloblastoma. Science 331: 435-439.
63. Pei Y., Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H., Korshunov A, Read TA, Sun JL, et al. 2012. An animal model of MYC-driven medulloblastoma. Cancer Cell 21: 155-167.
64. Pfaff E., RemkeM, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schottler A, Jorch N, et al. 2010. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 28: 5188-5196.
65. Pfister S., RemkeM, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, et al. 2009. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27: 1627-1636.
66. Psathas J. N, Thomas-Tikhonenko A. 2013. MYC and the art of microRNA maintenance. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014175.
67. Pugh T. J, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, Carneiro MO, Carter SL, Cibulskis K., Erlich RL, et al. 2012. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488: 106-110.
68. Rahl PB, Young RA. 2013. Myc and transcription elongation. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect. a014340.
69. Rahman S., Sowa ME, Ottinger M, Smith JA, Shi Y, Harper JW, Howley PM. 2011. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol 31: 2641-2652.
70. Rausch T., Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J., Jager N, Remke M, Shih D, Northcott PA, et al. 2012. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148: 59-71.
71. Robinson G., Parker M, Kranenburg TA, Lu C, Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, et al. 2012. Novel mutations target distinct subgroups of medulloblastoma. Nature 488: 43-48.
72. RousselMF, Hatten ME. 2011. Cerebellum development and medulloblastoma. Curr Topics Dev Biol 94: 235-282.
73. Roussel M., Saule S, Lagrou C, Rommens C, Beug H, Graf T, Stehelin D. 1979. Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation. Nature 281: 452-455.
74. Rutkowski S., BodeU, Deinlein F, Ottensmeier H, Warmuth-Metz M., Soerensen N, Graf N, Emser A, Pietsch T, Wolff JE, et al. 2005. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. NEngl J Med 352: 978-986.
75. Salvatori B., Iosue I, Djodji Damas N, Mangiavacchi A, Chiaretti S., Messina M, Padula F, Guarini A, Bozzoni I, Fazi F., et al. 2011. Critical role of c-Myc in acute myeloid leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2. Genes Cancer 2: 585-592.
76. Shtivelman E., Bishop JM. 1989. The PVT gene frequently amplifies withMYC in tumorcells. MolCell Biol 9: 1148-1154.
77. Sorrell MC, McFerrin L, Eisenman RN. 2013. An overviewof MYC and its interactome. Cold Spring Harb PerspectMed doi: 10.1101/cshperspect.a014357.
78. Swartling F. J, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, et al. 2010. Pleiotropic role for MYCN in medulloblastoma. Genes Dev 24: 1059-1072.
79. Swartling F. J, Savov V, Persson AI, Chen J, Hackett CS, Northcott P. A, Grimmer MR, Lau J, Chesler L, Perry A, et al. 2012. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell 21: 601-613.
80. Takwi A. A, Li Y, Becker Buscaglia LE, Zhang J, Choudhury S, Park A. K, Liu M, Young KH, Park WY, Martin RC, et al. 2012. A statin-regulated microRNA represses human c-Myc expression and function. EMBO Mol Med 4: 896-909.
81. Taylor M. D, Northcott PA, Korshunov A, RemkeM, Cho YJ, Clifford S. C, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A., et al. 2012. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol 123: 465-472.
82. ThomasWD, Chen J, Gao YR, Cheung B, Koach J, Sekyere E, Norris M. D, Haber M, Ellis T, Wainwright B, et al. 2009. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression. Oncogene 28: 1605-1615.
83. Thompson M. C, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau C. C, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, et al. 2006. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24: 1924-1931.
84. Uziel T., Zindy F, Xie S, Lee Y, Forget A, Magdaleno S, Rehg JE, Calabrese C, Solecki D, Eberhart CG, et al. 2005. The tumor suppressors Ink4c and p53 collaborate independentlywith Patched to suppress medulloblastoma formation. Genes Dev 19: 2656-2667.
85. Uziel T., Karginov FV, Xie SQ, Parker JS, Wang YD, Gajjar A, HeL, EllisonD, Gilbertson RJ, Hannon G, et al. 2009. The miR-17 similar to 92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci 106: 2812-2817.
86. Vennstrom B., Sheiness D, Zabielski J, Bishop JM. 1982. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol 42: 773-779.
87. Ventura A., Jacks T. 2009. MicroRNAs and cancer: Short RNAs go a long way. Cell 136: 586-591.
88. Weeraratne S. D, AmaniV, Teider N, Pierre-Francois J, Winter D, KyeMJ, Sengupta S, Archer T, RemkeM, Bai AH, et al. 2012. Pleiotropic effects of miR-183_96_182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol 123: 539-552.
89. Wey A., Martinez Cerdeno V, PleasureD, Knoepfler PS. 2010. c-and N-myc regulate neural precursor cell fate, cell cycle, and metabolism to direct cerebellar development. Cerebellum 9: 537-547.
90. Zhao X., Liu Z, Yu L, Zhang Y, Baxter P, Voicu H, Gurusiddappa S, Luan J, Su JM, Leung HC, et al. 2012. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro-oncol 14: 574-583.
91. Zindy F., Knoepfler PS, Xie S, Sherr CJ, Eisenman RN, Roussel MF. 2006. N-Myc and the cyclin-dependent kinase inhibitors pp18Ink4c and p27Kip1 coordinately regulate cerebellar development. Proc Natl Acad Sci 103: 11579-11583.
92. Zindy F., Uziel T, Ayrault O, Calabrese C, Valentine M, Rehg JE, Gilbertson RJ, Sherr CJ, Roussel MF. 2007. Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Res 67: 2676-2684.
93. Zuber J., Rappaport AR, LuoW, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Taylor MJ, et al. 2011a. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev 25: 1628-1640.
94. Zuber J., Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. 2011b. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.